Cancer patients suffering from chemotherapy-induced nausea and vomiting will have to wait for..

Wednesday 7 March 2012, Amsterdam

No novel drugs for treating nausea for cancer patients are expected to be launched in the near future.

Cancer patients suffering from chemotherapy-induced nausea and vomiting (CINV) will have to wait for the pharmaceuticals market to catch up with their needs, new drug research from industry analysis specialist.

The study found that the CINV drug developmental pipeline is weak due to a lack of novel molecules. The developmental pipeline for CINV consists of 12 molecules in various stages of development. However, the majority of the pipeline molecules are merely product extensions or new formulations of existing drugs, and the one molecule offering a novel mechanism of action is in the very early stages of development. The lack of a strong developmental pipeline is expected to not only disappoint clinicians and patients, but also leads to the slow growth of the CINV therapeutics market for at least the next decade.

Due to its weak product pipeline, they estimates that the value of the CINV therapeutics market is forecast to show the moderate growth in the next eight years, reaching a value of US$1.8 billion by 2019. This is due to the patent expiries of Aloxi and Emend, and the subsequent launch of generics in the forecast period.

The global CINV therapeutics market was found to be worth US$1.2 billion in 2011 and grew at a compound annual growth rate (CAGR) of 6.1% from $892m in 2006.

During this period, the market experienced a high uptake of premium, high-cost antiemetics such as Aloxi (palonosetron) and Emend (aprepitant). The launches of Emend and Promend (fosaprepitant) in Japan in 2009 and 2011 respectively also contributed to market growth during this period.

The situation may begin to improve for cancer sufferers, as pharmaceutical companies will need to focus on compliance with patient needs if they are to succeed in capturing market share from the current leaders. While some clinicians would argue that the current marketed products for CINV offer a high efficacy, safety and affordability, others say that up to 80% of cases of CINV could be eliminated if pharmaceuticals companies increased their investment in research and clinical trials.

Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The report is an essential source of information and analysis on the global chemotherapy-induced nausea and vomiting (CINV) market. The report identifies the key trends shaping and driving the global CINV market, and provides insight into the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CINV sector.